# CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism

> **NCT02937558** · PHASE2 · COMPLETED · sponsor: **Xeris Pharmaceuticals** · enrollment: 5 (actual)

## Conditions studied

- Congenital Hyperinsulinism

## Interventions

- **DRUG:** Glucagon
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02937558
- **Lead sponsor:** Xeris Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10
- **Primary completion:** 2018-09
- **Final completion:** 2018-10
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2019-12-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02937558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02937558, "CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02937558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*